Allogene Therapeutics Inc. (ALLO)
ALLO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.29
-7.86% on the day
Market cap
$445.7M
Small cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$190.9M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ALLO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001737287 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$190.9M |
| Operating income | -$209.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $51.7M |
| Total assets | $415.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-09-02 |
| Latest proxy | DEFA14A | 2026-05-28 |
Source: SEC EDGAR submissions feed, 581 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.2% |
| 1 month | -26.2% |
| 3 months | -29.1% |
| Year to date | -7.3% |
| 1 year | 0.0% |
| From 52-week high | -58.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AGMB | AgomAb Therapeutics NV | $8.81 | -3.08% | $433.9M |
| ENTX | Entera Bio Ltd. | $2.49 | -6.04% | $433.1M |
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.62 | -6.90% | $431.2M |
| PROK | ProKidney Corp. | $1.57 | -5.99% | $474.6M |
| TECX | Tectonic Therapeutic Inc. | $21.31 | -4.65% | $416.6M |
| RGNX | REGENXBIO Inc. | $7.26 | -6.56% | $479.3M |
| ZURA | Zura Bio Limited | $4.23 | +5.75% | $405.4M |
| VALN | Valneva SE | $5.56 | -6.24% | $527.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier